Economy & Policy

Million-dollar gene therapies expose U.S. insurers’ coverage dilemma

Marc Boutin argues that gene therapies costing more than $1 million can, in many cases, cure diseases for life, but U.S. insurer incentives and short payment horizons can impede coverage.

By Grace Kim

4 min read

Op-Ed: America’s healthcare system isn’t sustainable. What would a better alternative look like?
Op-Ed: America’s healthcare system isn’t sustainable. What would a better alternative look like?DarkoStojanovic / pixabay

What's News

  • Marc Boutin says some gene therapies have price tags exceeding $1 million.
  • In many cases, a one-time gene-therapy dose can cure a disease for life, Boutin says.
  • Boutin says these treatments can prevent millions of dollars in hospitalization and other care spending.
  • His proposal has three parts: price-and-quality competition, fuller cost-benefit valuation and redesigned payment rules.
  • IVI president and CEO Marc Boutin is a three-time cancer survivor and caregiver.

By Grace Kim

Some gene therapies cost more than $1 million, and in many cases one dose can cure a patient’s disease for life, Marc Boutin says. In his account, the price and the cure expose a fault line in U.S. health insurance: the organization paying for treatment today may collect none of the savings it prevents tomorrow.

Boutin, J.D., is president and CEO of IVI and a three-time cancer survivor and caregiver. In an opinion column, he argues that the U.S. healthcare system is unsustainable because it fails families, not because it lacks medical talent, but because its payment system never defined the outcomes it should produce.

What does the current system fail to solve?

Boutin says America has the world’s most talented doctors and best hospitals. American researchers develop the lion’s share of new medicines, and more treatments are available in the U.S. than in peer nations, at least in theory.

Yet he says the system cannot agree on what healthcare should accomplish, which outcomes matter most or what tradeoffs it will tolerate. Without that shared understanding, companies default to protecting their short-term finances, even when the choice runs counter to the long-term interests of patients, families and society.

Boutin traces that mismatch to insurance churn. He says Americans regularly switch insurers after changing jobs, moving states, retiring and enrolling in Medicare, or choosing plans that better fit their needs. A new insurer may shoulder the upfront cost of an expensive treatment while the eventual savings accrue elsewhere.

The problem is timing: an insurer pays today, while another payer may collect tomorrow’s savings.

Why can incentives restrict access to cost-effective cures?

Boutin uses gene therapies to show how timing distorts access. The treatments target underlying genetic malfunctions and mutations that cause certain diseases. In many cases, one dose cures the disease for life and prevents millions of dollars in spending on hospitalizations and other care, he says.

Multiple gene therapies remain cost-effective even when their price tags exceed $1 million, according to Boutin. But an insurer that covers one may see only a fraction of the return before the patient switches plans. He says that timing creates a strong incentive to limit access even when the treatment offers good value over a lifetime.

He describes the behavior as rational for an individual insurer or employer but irrational for society as a whole. The narrow financial logic works against the broader goal of preventing complications and long-term costs.

The core problem is time: insurers pay up front, while long-term savings may belong to another payer.

How would Boutin redesign payment and insurance?

Boutin calls for a genuinely market-based system. He writes: “We need a genuinely market-based system in which providers, drug companies, and insurers can transparently compete for customers on both price and quality.”

He says competition cannot work unless new valuation metrics capture the full costs and benefits of different treatments and care models. His proposal has three linked elements:

  • Let providers, drug companies and insurers compete for customers on price and quality.
  • Measure the full costs and benefits of treatments and care models.
  • Change payment and insurance rules so organizations are rewarded, not penalized, for investing in patients’ long-term health.

In Boutin’s design, upfront payment for a durable cure becomes an investment in avoided illness, rather than a cost an insurer loses when the patient changes plans.

The reform goal is to make prevention and durable cures financially rational for the payer taking the risk.

Can stakeholders act before Washington intervenes?

Boutin starts from broad dissatisfaction. He says virtually no one in America is satisfied with the status quo, including doctors, hospital executives, drug and insurance company leaders, and patients. Policymakers in both parties are planning ambitious healthcare overhauls, according to him.

He asks whether stakeholders can set aside their differences and work together now rather than wait for Washington to impose changes from above. Their task, he says, is to reimagine and redesign the system around a shared vision and a shared definition of success, measured in patients’ long-term physical, mental and financial health.

Boutin previously served as CEO of the National Health Council, where he led policy initiatives that helped shape national health care reform. His warning is blunt: “If they cannot, Washington will eventually impose changes from above.”

If voluntary bargaining stalls, Boutin expects Washington to impose a redesign whose defining choices remain unsettled.

Source: gilmermirror.com

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

2,387 articles

Related articles

« Previous articleNext article »